Literature DB >> 23390372

Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Paulette Mhawech-Fauceglia1, Dan Wang, Liaquat Ali, Shashikant Lele, Michael A Huba, Song Liu, Kunle Odunsi.   

Abstract

The aims of this study were to evaluate the prognostic significance of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in patients with familial ovarian cancer. Clinical and pathological information were retrieved from the Gilda Radner Familial Ovarian Cancer Registry (GRFOCR) in Buffalo, NY. Immunohistochemistry was performed on paraffin-embedded tissue specimens of GRFOCR participants using specific antibodies for CD3+, CD8+, CD25+, FOXP3+, CD68+, and CD163+. The correlation between the frequencies of TILs and TAMs and clinic-pathologic parameters were determined. Overall survival was determined using univariate and multivariate Cox proportional hazards models. High tumor grade correlated with higher frequencies of CD3+ (p = 0.019), CD68+ (p = 0.025), CD163+ (p = 0.018), and T(reg) (CD25+ FOXP3+) (p = 0.024) cells. Higher stage correlated with higher frequencies of CD163+ cells (p = 0.012). There were correlations between the frequencies of CD68+ and CD3+ (p = 0.029), between T(reg) and each of CD3+ (p = 0.002), CD8+ (p = 0.018), and CD68+ (p = 0.028) cells. In univariate analysis, age and T(reg) significantly predicted patient survival. In multivariate survival analysis, T(reg) frequency was the only significant predictor of prognosis in patients with familial ovarian cancer [HR = 0.92; 95% CI 0.87 - 0.98; p = 0.012]. We concluded that interaction between TILs and TAMs in familial EOC also exists, and tumors with high T(reg) frequencies have a more favorable outcome. Thus, therapeutic strategies to modulate tumor T(reg) infiltration could be beneficial for patients with familial ovarian cancer.

Entities:  

Keywords:  CD count; familial ovarian cancer; patient outcome

Mesh:

Year:  2013        PMID: 23390372      PMCID: PMC3559189     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  34 in total

Review 1.  Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry.

Authors:  M Steven Piver
Journal:  Gynecol Oncol       Date:  2002-04       Impact factor: 5.482

Review 2.  TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells.

Authors:  Sharon M Wahl; Jennifer Swisher; Nancy McCartney-Francis; Wanjun Chen
Journal:  J Leukoc Biol       Date:  2004-02-13       Impact factor: 4.962

Review 3.  Histopathologic grading of ovarian carcinoma: a review and proposal.

Authors:  S G Silverberg
Journal:  Int J Gynecol Pathol       Date:  2000-01       Impact factor: 2.762

4.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

5.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Authors:  H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02-15       Impact factor: 11.025

Review 6.  Derangement of immune responses by myeloid suppressor cells.

Authors:  Paolo Serafini; Carmela De Santo; Ilaria Marigo; Sara Cingarlini; Luigi Dolcetti; Giovanna Gallina; Paola Zanovello; Vincenzo Bronte
Journal:  Cancer Immunol Immunother       Date:  2003-10-30       Impact factor: 6.968

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 8.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 10.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  24 in total

1.  Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.

Authors:  Nonna Kolomeyevskaya; Kevin H Eng; Anm Nazmul H Khan; Kassondra S Grzankowski; Kelly L Singel; Kirsten Moysich; Brahm H Segal
Journal:  Gynecol Oncol       Date:  2015-05-20       Impact factor: 5.482

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 3.  Recent advances in CD8+ regulatory T cell research.

Authors:  Yating Yu; Xinbo Ma; Rufei Gong; Jianmeng Zhu; Lihua Wei; Jinguang Yao
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

4.  TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.

Authors:  Rosekeila Simões Nomelini; Luciano Eliziário Borges Júnior; Cid Almeida de Lima; Ana Flávia Carrijo Chiovato; Douglas Côbo Micheli; Beatriz Martins Tavares-Murta; Eddie Fernando Candido Murta
Journal:  Clin Exp Med       Date:  2018-05-25       Impact factor: 3.984

Review 5.  Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.

Authors:  Kelly L Singel; Brahm H Segal
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

6.  Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Authors:  Jacek R Wilczyński; Marek Nowak
Journal:  Exp Suppl       Date:  2022

7.  Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.

Authors:  Lauren C Peres; Christelle Colin-Leitzinger; Sweta Sinha; Jeffrey R Marks; Jose R Conejo-Garcia; Anthony J Alberg; Elisa V Bandera; Andrew Berchuck; Melissa L Bondy; Brock C Christensen; Michele L Cote; Jennifer Anne Doherty; Patricia G Moorman; Edward S Peters; Carlos Moran Segura; Jonathan V Nguyen; Ann G Schwartz; Paul D Terry; Christopher M Wilson; Brooke L Fridley; Joellen M Schildkraut
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-05-04       Impact factor: 4.090

8.  Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.

Authors:  Christopher B Morse; Mirna N Toukatly; Mark R Kilgore; Kathy J Agnew; Sarah S Bernards; Barbara M Norquist; Kathryn P Pennington; Rochelle L Garcia; John B Liao; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2019-02-23       Impact factor: 5.304

9.  The impact of inflammatory cells in malignant ascites on small intestinal ICCs' morphology and function.

Authors:  Jing Li; Dan Kong; Yan He; Xiuli Wang; Lei Gao; Jiade Li; Meisi Yan; Duanyang Liu; Yufu Wang; Lei Zhang; Xiaoming Jin
Journal:  J Cell Mol Med       Date:  2015-06-18       Impact factor: 5.310

10.  Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy.

Authors:  Allison G Roy; J Michael Robinson; Prannda Sharma; Alba Rodriguez-Garcia; Mathilde A Poussin; Cheryl Nickerson-Nutter; Daniel J Powell
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.